← Leaderboards
Stig K. Hansen
Carmot Therapeutics, Inc.
$2,211,071
Attributed
$2,211,071
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $987.6K · FY2010–14$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$2,211,071 · 2
By mechanism
R44$1,911,764 · 1
R43$299,307 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Innovative Technologies”
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$303,754,336
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$240,302,862
- Richard A Gibbs · Baylor College Of Medicine$236,845,267
- David Heimbrook · Leidos Biomedical Research, Inc.$221,646,720
- Dennis R. Burton · Scripps Research Institute$199,212,539
- George R Seage · Abt Associates, Inc.$171,638,284
Research focus
Innovative TechnologiesMalignant NeoplasmsDrug KineticsInnovationLeadLigandsAngiogenesisBinding (Molecular Function)InflammatoryBortezomibEvolutionIn VivoBaseCell ProliferationCellsCell SurvivalCommercializationCommunicationComplexInflammationDrug CandidateDrug DiscoveryEnvironmentNf-Kappa B
Grant awards (3)
Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of$924,148
R44 · FY2014 · CA · contact PI
Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of$987,616
R44 · FY2013 · CA · contact PI
Discovery of small molecule drug candidates that disrupt the NEMO/IKK signaling c$299,307
R43 · FY2010 · CA · contact PI